Jun 27, 2024, 18:05
Adagrasib plus Cetuximab shows efficacy and safety in metastatic colorectal cancer
Iván R. González, Medical Oncologist at Centro Oncológico Integral, shared on X:
“In the KRYSTAL-1 trial, the combination of Adagrasib plus Cetuximab shows efficacy and safety in metastatic colorectal cancer with KRAS G12C mutation. ORR was 34%, with a median duration of 5.8 months and overall survival of 15.9 months.
These data suggest a new standard of care and highlight the importance of KRAS G12C testing.”
Source: Iván R. González/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 08:19
Feb 21, 2025, 06:20
Feb 20, 2025, 11:19
Feb 20, 2025, 11:13
Feb 20, 2025, 11:08
Feb 20, 2025, 11:00